33
Participants
Start Date
April 12, 2017
Primary Completion Date
January 30, 2018
Study Completion Date
January 30, 2018
MK-5160 16 nmol/kg
MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
MK-5160 32 nmol/kg
MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
MK-5160 64 nmol/kg
MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
Glargine 0.4 U/kg
Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
Placebo to Glargine
Placebo to glargine, subcutaneous injection administered daily for 12 days
Placebo to MK-5160
Placebo to MK-5160, subcutaneous injection administered daily for 12 days
Dextrose
20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
Glargine 0.6 U/kg
Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
ProSciento Inc. ( Site 0001), Chula Vista
Merck Sharp & Dohme LLC
INDUSTRY